| Trial ID: | L2716 |
| Source ID: | NCT01105429
|
| Associated Drug: |
Bms-820132
|
| Title: |
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Non-Insulin-Dependent
|
| Interventions: |
DRUG: BMS-820132|DRUG: BMS-820132|DRUG: BMS-820132|DRUG: BMS-820132|DRUG: BMS-820132|DRUG: BMS-820132|DRUG: BMS-820132|DRUG: BMS-820132|DRUG: BMS-820132|DRUG: Placebo|DRUG: Placebo
|
| Outcome Measures: |
Primary: Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments, Within 5 days of study drug administration | Secondary: Exposure to the investigational drug and its metabolites, Within 2 days after study drug administration|Pharmacodynamic activity of the investigational drug on biomarkers, Within 2 days after study drug administration|Excretion of the investigational drug and metabolites from the body, Within 2 days after study drug administration
|
| Sponsor/Collaborators: |
Sponsor: Bristol-Myers Squibb
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
56
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-05
|
| Completion Date: |
2010-10
|
| Results First Posted: |
|
| Last Update Posted: |
2011-03-09
|
| Locations: |
Profil Institute For Clinical Research, Inc. (Picr), Chula Vista, California, 91911, United States|Clinical Pharmacology Of Miami Inc., Miami, Florida, 33014, United States|Elite Research Institute, Miami, Florida, 33169, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01105429
|
